Observatory · observe first

Follow the allocation change

Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.

Historical time machine
Historical observation
20182026
Universe›Health Care›Biotechnology›Biotechnology

1 · Sector

Weight and 12M allocation change

Information Technology41.9%+7.32 ppEnergy2.5%+0.19 ppConsumer Discretionary11.8%-0.20 ppMaterials2.0%-0.21 ppCommunication Services2.4%-0.32 ppReal Estate2.0%-0.41 ppUtilities2.4%-0.43 ppIndustrials9.6%-0.50 ppHealth Care9.7%-1.47 ppConsumer Staples5.7%-1.52 ppFinancials9.8%-2.46 pp

2 · Industry

Inside Health Care

Health Care Equipment1.51%-1.12 ppPharmaceuticals3.80%+0.22 ppBiotechnology1.68%-0.18 ppLife Sciences Tools & Services0.80%-0.12 ppHealth Care Distributors0.34%-0.09 ppManaged Health Care0.86%-0.08 ppHealth Care Services0.42%-0.07 ppHealth Care Facilities0.15%-0.06 ppHealth Care Technology0.07%+0.04 ppHealth Care Supplies0.08%-0.01 pp

3 · Sub-industry

Inside Biotechnology

Biotechnology1.68%-0.179 pp
Concentrated

Most of this industry's losses came from a few companies.

View all contributions →
Biotechnology · weight
1.68%
Industry change · 12M
-0.18 pp
Biotechnology · contribution
-0.179 pp
Company participation
88%
of industry constituents above their 6M weight average

4 · Companies driving this sub-industry

May 2026 · sorted by absolute contribution to 12-month change

CompanyCountryMarket capUniverse weight3M contribution12M contribution12M price returnAbove 6M weight average
AbbVie →
ABBV
United States$384.7bn0.667%+0.103 pp-0.078 pp+20.8%Yes
Vertex Pharmaceuticals →
VRTX
United States$113.6bn0.197%+0.024 pp-0.060 pp+1.2%Yes
Amgen →
AMGN
United States$181.8bn0.315%+0.028 pp-0.036 pp+20.4%Yes
Gilead Sciences →
GILD
United States$166.9bn0.289%+0.035 pp-0.021 pp+25.4%Yes
Moderna →
MRNA
United States$18.7bn0.032%+0.003 pp+0.009 pp+77.7%Yes
Biogen →
BIIB
United States$28.9bn0.050%+0.012 pp+0.007 pp+51.0%Yes
Incyte →
INCY
United States$19.3bn0.033%+0.006 pp+0.005 pp+48.7%Yes
Regeneron Pharmaceuticals →
REGN
United States$57.8bn0.100%-0.001 pp-0.004 pp+26.1%No

Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.